August 2018

Publication in American Journal of Physiology Heart and Circulatory Physiology Titled "A novel fibroblast activation inhibitor attenuates left ventricular remodeling and preserves cardiac function in heart failure” highlights NovoMedix’s novel antifibrotic small molecule program that effectively prevents fibroblast activation. A lead compound reduced the formation of cardiac fibrosis and preserved cardiac function in a murine model of transaortic constriction induced heart failure with reduced ejection fraction. The unique combination of biological activities of these compounds should have significant impact not only in heart failure but in fibrotic disease that affect other major organs such as liver, lung, and kidney as well as malignant tumors that are highly dependent on the stroma such as pancreatic and breast cancer.